Pakistan Implantable Devices: Automatic Class D under the Rules

1. Key takeaways

In Pakistan, all implantable devices automatically fall into Class D (high risk) and attract the highest tier of requirements: they must follow the registration route (Form-7A on the import path), submit complete conformity assessment evidence (including the design examination certificate specific to Class D), and, in practice, provide approval evidence from reference regulatory authorities (USA, Japan, Australia, Canada, EU member states, among others) in order to enter the routine review rhythm. Taken together, these requirements make implantable devices the most evidence-intensive product family in the Pakistani system, and they make the certification chain — quality system, product certificate and design examination — the critical path of the entire project rather than a supporting activity.

• Implantability alone fixes the class; no five-dimension judgement is needed to reach Class D.
• The registration route and its deeper evidence burden apply in full.
• Reference-country approval evidence is the practical key to a predictable review timeline.
• Refurbished devices follow their own statutory definitions and cannot be filed as new products.
• The donation channel under Rule 24A is a separate exception and is never used to route commercial stock.

2. Legal basis

The table below lists the provisions governing Class D implantable devices, from the four-grade structure to the certificate validity period and the refurbished-device definitions. Two provisions deserve particular attention when planning: the Rule 15(2) evidence requirements, which drive the certification chain, and the S.R.O. 559(I)/2022 definitions, which decide how non-standard stock must be presented.

3. Expert insights

Insight 1: Implant means Class D is a hard rule, not a presumption. Classification generally requires judgement across five dimensions, but implantable devices apply the highest grade directly, with no middle ground. For orthopaedic implants, cardiovascular implants and dental implant products, project budgets and schedules should be prepared on a Class D basis from day one. There is no argument available that a particular implant is simpler than others of its kind, so planning exercises that assume a lighter treatment for a technically simple implant misallocate resources from the very first estimate. The automatic rule also simplifies classification work in one respect: once implantability is confirmed, the five-dimension analysis is not needed to fix the class, and the team can move directly to building the Class D evidence plan.

Insight 2: The extra threshold for Class D is the design examination certificate. Class B/C require only a QMS certification issued by a notified body; Class D additionally requires a design examination (design examination) certificate on top of that. This is the only, but critical, difference between Class D and Class C at the evidence level. It changes who must be engaged on the certification side, because design examination is a distinct activity from QMS certification, and it changes the calendar, since the two certificates cannot be produced in the same single audit visit the way a QMS certificate alone can. Manufacturers holding a QMS certificate often assume it covers the Class D requirement; it does not, and discovering the design examination gap after submission converts a planned review into a remediation exercise.

Insight 3: Bringing the definition of refurbished devices into the rules closed the loophole of refurbishing devices and selling them as new. S.R.O. 559(I)/2022 added the definitions of “refurbished device” and “refurbishment”, and made clear that refurbishment can include dismantling, inspection, replacement of parts, reassembly, testing against the original specifications, and labelling as a refurbished device. This means refurbished devices cannot be filed through the new-product pathway. Importers previously trading in the grey zone between second-hand equipment and new stock now face a defined category, and any consignment containing refurbished units must be declared and assessed on the refurbished basis, not passed off as standard new product. The definitions also give reviewers a precise vocabulary, which shortens arguments about what a unit actually is and shifts those arguments to the documentary record.

4. Practical recommendations

• The first task GRZAN performs on a Class D project is confirming the availability of three documents: the ISO 13485 certificate, the CE certificate and the EC design examination certificate.
• If the third document is missing, the project cannot proceed on the conventional route; we inform the client in advance of two remedial routes: complete the EU-route design examination, or switch to other reference-country approval evidence and confirm its acceptability with MDMC in writing.
• This judgement must occur before submission, not after a deficiency letter arrives.
• Where the client already holds overseas NRA or notified body evidence, that evidence is included in the file, as Rule 15(2) requires it to be submitted where held.
• For any stock containing refurbished units, the filing is prepared on the refurbished basis as defined by S.R.O. 559(I)/2022.
• Certificate planning assumes the 5-year validity under Rule 15(4), with renewal work scheduled inside the validity window.

5. Verification checklist

• □ Confirmed the product is implantable → Class D
• □ Confirmed the registration route applies (import Form-7A)
• □ ISO 13485 certificate has been prepared
• □ CE certificate or reference-country approval evidence has been prepared
• □ The EC design examination certificate has been prepared (specific to Class D)
• □ Refurbished devices have been handled separately under the refurbishment definitions, not through the new-product pathway

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com